BCR-ABL+ acute lymphoblastic leukemia (ALL) closely resembles the aggressive lymphoid BC of CML and is prone to relapse with current therapies [1–5]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.